What makes UpToDate so powerful?

  • over 11000 topics
  • 22 specialties
  • 5,700 physician authors
  • evidence-based recommendations
See more sample topics
Find Print
0 Find synonyms

Find synonyms Find exact match

Transient hypogammaglobulinemia of infancy
UpToDate
Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate®
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
Transient hypogammaglobulinemia of infancy
View in Chinese
All topics are updated as new evidence becomes available and our peer review process is complete.
Literature review current through: Aug 2017. | This topic last updated: Oct 24, 2016.

INTRODUCTION — Transient hypogammaglobulinemia of infancy (THI) was classically described as an accentuation and prolongation of the "physiologic" immunoglobulin nadir that is normally observed during the first three to six months of life (figure 1) [1,2]. However, there remains no full agreement among immunologists regarding the definition of THI due to the absence of specific markers or a genetic signature. While some use sweeping inclusion criteria such as a reduction in any immunoglobulin (immunoglobulin G [IgG], immunoglobulin A [IgA], immunoglobulin M [IgM]), beyond the physiologic nadir [2-7], most agree that low IgG is essential for considering the diagnosis [8-12].

The definition proposed by the International Union of Immunological Societies (IUIS) committee [13] calling for obligatory low IgG and IgA in THI poses multiple challenges. It excludes all cases of isolated, transient low IgG (4 to 45 percent of cases of classically defined THI [3,8,10,14]) and also includes other entities such as hyper-IgM syndrome and common variable immunodeficiency (CVID) [15]. The European Society for Immunodeficiencies (ESID) has proposed the term "unclassified hypogammaglobulinemia" for children in the first three years of life with low IgG levels, reserving THI for those children that recover by age four years [16].

The authors of this topic use a more conservative and balanced definition, which, on one hand, is flexible enough to include most cases historically considered to have THI but sufficiently restrictive to prevent confusion with other possible conditions. It encompasses low serum IgG levels in the presence or absence of low IgA or IgM (consistent with the ESID criteria) and normalization of IgG levels, as well as specific antibodies, over time. Hypogammaglobulinemia associated with a reduction in circulating B cells, abnormal cellular immunity, and syndromic features is excluded from the definition of THI.

It is important to recognize that the diagnosis of THI is made retrospectively. It is one of several possible diagnoses considered in the heterogeneous population of young children presenting with recurrent infections and low immunoglobulins.

This topic reviews the clinical features, diagnosis, and management of THI. Other humoral immune defects are reviewed in greater detail separately. (See "Primary humoral immunodeficiencies: An overview".)

EPIDEMIOLOGY — The estimated incidence of THI is between 0.061 and 1.1 per 1000 live births [4,17]. Some cohorts demonstrated a disproportionate number of male infants (up to 70 percent) [3,14,18], but this finding was not supported by other studies [12,19,20].

PATHOGENESIS — The molecular basis underlying THI remains elusive [2,8-10,21-28], although there are ongoing attempts to determine the pathogenesis of this disorder.

A defect in B cell CD19 expression was proposed as a possible cause of reduced immunoglobulin production in THI in a single study [29]. However, other groups have found increased expression of CD19 in patients with THI [30]. This discordant result may be explained by the difference in study populations. The first study was performed on a highly consanguineous population, while the second study was done on a presumed genetically heterogeneous North American group.

A CD19 defect as a cause for THI is also challenged by the findings that B cell development and in vitro immunoglobulin production are normal in THI [11] but not in CD19 deficiency [31]. In addition, CD5+ B cells are normal in THI but low in CD19 deficiency [29].

Another proposed mechanism for the reduced immunoglobulin G (IgG) production seen in THI is an immunoglobulin switch defect. However, this theory cannot be reconciled with the normal in vitro immunoglobulin production [22] and the temporary nature of THI.

CLINICAL MANIFESTATIONS — The clinical manifestations of THI have remained consistent in large surveys and prospective studies [15,18]. Most patients suffer upper and lower respiratory tract infections (40 to 90 percent), and the second most common feature is allergic disorders (approximately 30 to 50 percent). Rare manifestations include urinary tract infections, gastroenteritis, and invasive infections [18,19,29].

Recurrent or unusual infections — Most infants with THI are identified because immunoglobulin measurement was performed due to a history of recurrent infections starting early in life. The spectrum of infections ranged from recurrent upper respiratory infections (URIs), otitis media, bronchitis, and urinary tract infections to severe, invasive infections, such as bacteremia and bacterial meningitis [9,18,20-22]. The initial indication for immunologic evaluation was recurrent URIs in one-half of these patients. Other indications included recurrent gastroenteritis, severe varicella, and prolonged oral thrush [8].

Atopic features — Atopic manifestations are frequently reported in patients with THI [4,6-8]. These include increased immunoglobulin E (IgE) concentrations and food allergy [32]; symptoms of either atopic disease or food allergy/intolerance without a history of recurrent infections [17]; and severe eczema (along with sensitization to certain common food allergens) that resolved with systemic glucocorticoids, relapsed with topical corticosteroids, and ultimately resolved with normalization of immunoglobulin G (IgG) levels [33].

Asymptomatic — Some infants with THI are asymptomatic, and the diagnosis is recognized because they had an immune evaluation, including screening of serum immunoglobulin levels, due to a family history of primary immunodeficiency [4,24].

LABORATORY FINDINGS — The laboratory hallmarks of THI include the following:

Serum immunoglobulins – Immunoglobulin G (IgG) is at least two standard deviations below the mean for age-matched controls, with or without diminished levels of immunoglobulin A (IgA) or immunoglobulin M (IgM) (table 1).

Specific antibodies – Most patients with THI have normal antibody responses to infections or to immunizations at presentation, while the remainder normalize by the time of resolution of THI [12,30]. In addition to normal antibodies found against protein antigens (such as tetanus), antipolysaccharide antibodies also appear comparable with controls in most [4,5,25], but not all [8,16], children. (See "Assessing the immunologic response to vaccination".)

Immunophenotyping and T cell function – Most studies have found intact lymphocyte subpopulations, including the level of memory and class-switched B cells [5,8,9,21,25]. In addition, studies have shown normal in vitro responses to mitogens [5,8,9,21,25] and normal production of IgG [22]. There are some cases of contrary findings; however, those patients may have other classified immunodeficiencies rather than THI. As examples, a single study reported transient numeric and functional abnormalities of CD4+ T cells [22], and a few other single-center studies have described lower or higher than normal expression of CD19 [29,30]. Another group identified reduced numbers of circulating IgM+ and "switched" (IgM-IgD-) memory B cells and an inability to produce IgG in vitro in some patients [15,34], a feature commonly observed in common variable immunodeficiency (CVID) [11,35,36].

Hematologic abnormalities – Hematologic manifestations are uncommon. Transient neutropenia was reported in two series [4,8], and a case of permanent neutropenia and another patient who developed acute lymphoblastic leukemia were also reported [8].

DIAGNOSIS — The diagnosis of THI cannot be made at presentation and is dependent upon obligatory criteria:

Serum immunoglobulin G (IgG) level must be recorded at more than two standard deviations below age-matched controls with or without diminished levels of other serum immunoglobulins on at least two occasions.

Immunoglobulins, as well as specific antibody formation, must normalize, usually during childhood or rarely during adolescence.

Other defined immunodeficiencies, as well as syndromes, should be excluded. (See 'Differential diagnosis' below.)

In order to establish the diagnosis, the following assessment is required:

History of type of past infections and a thorough physical examination (to exclude syndromes). (See "Laboratory evaluation of the immune system" and "Approach to the child with recurrent infections" and "Syndromic immunodeficiencies".)

Measurement of serum IgG, immunoglobulin A (IgA) and immunoglobulin M (IgM), as well as specific antibodies.

Immunophenotyping and/or proliferative response to mitogens should be assessed in suspected cases in order to exclude cellular immunodeficiency or agammaglobulinemia (X linked or autosomal recessive).

DIFFERENTIAL DIAGNOSIS — THI at presentation should be distinguished from other permanent forms of hypogammaglobulinemia [2]. Cases of X-linked or autosomal recessive agammaglobulinemia can be identified with relative ease by identifying low to absent B cells on flow cytometry and by confirming the diagnosis with genetic analysis [37-39]. However, more challenging are rare, leaky forms of these genetic defects that may present with circulating B cells, although antibody production is still aberrant [40,41]. (See "Flow cytometry for the diagnosis of primary immunodeficiencies", section on 'B cells' and "Agammaglobulinemia" and "Primary humoral immunodeficiencies: An overview".)

Early-onset common variable immunodeficiency (CVID) should also be considered in the differential diagnosis. The common denominator with this heterogeneous group of patients is low immunoglobulins (immunoglobulin G [IgG] and immunoglobulin A [IgA]), but an inability to produce specific antibodies sets this condition apart from THI. The overlap in presentation between these disorders can be observed in patients with CVID who gradually lose the ability to form antibodies and cases with THI who initially lack antibodies but eventually resolve. (See "Common variable immunodeficiency in children".)

Low immunoglobulins are also seen in patients with severe combined immunodeficiency. However, unlike THI, they distinctly present with very low lymphocyte counts, severe and recurrent viral or fungal infections, and failure to thrive. (See "Severe combined immunodeficiency (SCID): An overview".)

OUTCOME — By definition, THI should completely resolve, with return to normal serum immunoglobulin levels and response to immunizations by age four years [42]. Resolution of recurrent infections usually occurs by 9 to 15 months of age, while immunoglobulin G (IgG) levels typically normalize by two to four years of age [28,42-44]. Rarely, resolution may span a decade [8] and may include a transient phase during which IgG subclasses (especially IgG2) are temporarily low.

TREATMENT — Most patients with THI are observed and treated for infections as needed. However, patients with more frequent and/or more severe infections can be treated with antibiotic prophylaxis or immune globulin replacement therapy.

Antibiotic prophylaxis — Antibiotic prophylaxis is reserved for patients with recurrent respiratory and/or ear infections. The preferred option is a single daily dose of trimethoprim-sulfamethoxazole (5 mg/kg of the trimethoprim component) or amoxicillin (40 mg/kg). (See "Acute otitis media in children: Prevention of recurrence", section on 'Antibiotic prophylaxis'.)

Immune globulin replacement therapy — Most patients with THI have only mild infections and do not require immune globulin replacement. Replacement therapy is reserved for patients with recurrent, severe infections who fail to respond to antibiotic prophylaxis [42]. (See "Immune globulin therapy in primary immunodeficiency" and "Overview of intravenous immune globulin (IVIG) therapy".)

Immune globulin replacement therapy is used extensively, and the preparation has been shown to be very safe [40]. Still, a decision to use this treatment should take the following into consideration:

It is an expensive treatment.

It is a blood product, and, as such, it may potentially transmit new and previously unrecognized infective agents, in spite of extensive inactivation methods [45].

Mild adverse reactions are commonly associated with its administration. However, rarely, more severe reactions such as thromboembolic events have been reported. (See "Immune globulin therapy in primary immunodeficiency" and "Selective IgA deficiency: Clinical manifestations, pathophysiology, and diagnosis".)

Administering immunoglobulin may theoretically delay the endogenous synthesis of the patient's own immunoglobulins [46]. This was not observed among 43 THI patients with THI compared with 23 untreated controls [42].

Most patients with THI are treated with immunoglobulin for short periods of time, ranging from a single injection up to 18 months [12,21]. Cessation of treatment is usually based upon the frequency and severity of infection and increase of immunoglobulins other than immunoglobulin G (IgG). After discontinuation of therapy, patients should be followed periodically until a complete clinical and laboratory resolution is accomplished and sustained. (See 'Diagnosis' above.)

SOCIETY GUIDELINE LINKS — Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See "Society guideline links: Primary immunodeficiencies".)

SUMMARY

Transient hypogammaglobulinemia of infancy (THI) is a diagnosis of exclusion that is established in retrospect after any laboratory findings and clinical manifestations have resolved. It occurs in the absence of other immunodeficiency conditions. Although transient, it may persist beyond six months of age. (See 'Introduction' above and 'Diagnosis' above.)

Patients with THI typically present in infancy with recurrent upper respiratory infections (URIs). Urinary tract infections, gastroenteritis, and invasive infections are less frequent. Some patients may be asymptomatic. Up to one-third of patients with THI have atopic features, including allergic respiratory features and food allergies. (See 'Clinical manifestations' above.)

Patients with THI have immunoglobulin G (IgG) levels that fall at least two standard deviations below the mean for age-matched controls, with or without diminished values of other immunoglobulin isotypes. Specific antibodies to immunizations or infections are adequate in most patients at presentation and, in some, normalize with resolution of THI. (See 'Laboratory findings' above.)

The primary disorders to exclude are permanent forms of hypogammaglobulinemia, including X-linked or autosomal recessive agammaglobulinemia and common variable immunodeficiency (CVID). (See 'Differential diagnosis' above.)

Infections resolve in most patients by 9 to 15 months, and immunoglobulins normalize by three to four years of age. Rarely, resolution may be delayed beyond the first decade of life. (See 'Outcome' above.)

Antibiotic prophylaxis is reserved for patients with recurrent respiratory and/or ear infections. The preferred option is a single daily dose of trimethoprim-sulfamethoxazole (5 mg/kg of the trimethoprim component) or twice-daily amoxicillin (10 mg/kg per dose). (See 'Treatment' above.)

Immune globulin replacement therapy is reserved for patients with THI who have recurrent, severe infections and fail a trial of antibiotic prophylaxis. (See 'Treatment' above and "Immune globulin therapy in primary immunodeficiency".)

Use of UpToDate is subject to the  Subscription and License Agreement.

REFERENCES

  1. GITLIN D, JANEWAY CA. Agammaglobulinemia, congenital, acquired and transient forms. Prog Hematol 1956; 1:318.
  2. McGeady SJ. Transient hypogammaglobulinemia of infancy. In: Stiehm's Immune Deficiencies, Stiehm ER (Ed), Elsevier Limited, Oxford 2014. p.417.
  3. Keles S, Artac H, Kara R, et al. Transient hypogammaglobulinemia and unclassified hypogammaglobulinemia: 'similarities and differences'. Pediatr Allergy Immunol 2010; 21:843.
  4. Tiller TL Jr, Buckley RH. Transient hypogammaglobulinemia of infancy: review of the literature, clinical and immunologic features of 11 new cases, and long-term follow-up. J Pediatr 1978; 92:347.
  5. Kiliç SS, Tezcan I, Sanal O, et al. Transient hypogammaglobulinemia of infancy: clinical and immunologic features of 40 new cases. Pediatr Int 2000; 42:647.
  6. Kidon MI, Handzel ZT, Schwartz R, et al. Symptomatic hypogammaglobulinemia in infancy and childhood - clinical outcome and in vitro immune responses. BMC Fam Pract 2004; 5:23.
  7. Whelan MA, Hwan WH, Beausoleil J, et al. Infants presenting with recurrent infections and low immunoglobulins: characteristics and analysis of normalization. J Clin Immunol 2006; 26:7.
  8. Dalal I, Reid B, Nisbet-Brown E, Roifman CM. The outcome of patients with hypogammaglobulinemia in infancy and early childhood. J Pediatr 1998; 133:144.
  9. Kowalczyk D, Mytar B, Zembala M. Cytokine production in transient hypogammaglobulinemia and isolated IgA deficiency. J Allergy Clin Immunol 1997; 100:556.
  10. Rutkowska M, Lenart M, Bukowska-Strakovà K, et al. The number of circulating CD4+ CD25high Foxp3+ T lymphocytes is transiently elevated in the early childhood of transient hypogammaglobulinemia of infancy patients. Clin Immunol 2011; 140:307.
  11. Bukowska-Straková K, Kowalczyk D, Baran J, et al. The B-cell compartment in the peripheral blood of children with different types of primary humoral immunodeficiency. Pediatr Res 2009; 66:28.
  12. Cano F, Mayo DR, Ballow M. Absent specific viral antibodies in patients with transient hypogammaglobulinemia of infancy. J Allergy Clin Immunol 1990; 85:510.
  13. Picard C, Al-Herz W, Bousfiha A, et al. Primary Immunodeficiency Diseases: an Update on the Classification from the International Union of Immunological Societies Expert Committee for Primary Immunodeficiency 2015. J Clin Immunol 2015; 35:696.
  14. Karaca NE, Aksu G, Gulez N, et al. New laboratory findings in Turkish patients with transient hypogammaglobulinemia of infancy. Iran J Allergy Asthma Immunol 2010; 9:237.
  15. Moschese V, Graziani S, Avanzini MA, et al. A prospective study on children with initial diagnosis of transient hypogammaglobulinemia of infancy: results from the Italian Primary Immunodeficiency Network. Int J Immunopathol Pharmacol 2008; 21:343.
  16. Moschese V, Cavaliere FM, Graziani S, et al. Decreased IgM, IgA, and IgG response to pneumococcal vaccine in children with transient hypogammaglobulinemia of infancy. J Allergy Clin Immunol 2016; 137:617.
  17. Walker AM, Kemp AS, Hill DJ, Shelton MJ. Features of transient hypogammaglobulinaemia in infants screened for immunological abnormalities. Arch Dis Child 1994; 70:183.
  18. Qian JH, Zhu JX, Zhu XD, Chen TX. Clinical features and follow-up of Chinese patients with symptomatic hypogammaglobulinemia in infancy. Chin Med J (Engl) 2009; 122:1877.
  19. Kutukculer N, Gulez N. The outcome of patients with unclassified hypogammaglobulinemia in early childhood. Pediatr Allergy Immunol 2009; 20:693.
  20. McGeady SJ. Transient hypogammaglobulinemia of infancy: need to reconsider name and definition. J Pediatr 1987; 110:47.
  21. Dressler F, Peter HH, Müller W, Rieger CH. Transient hypogammaglobulinemia of infancy: Five new cases, review of the literature and redefinition. Acta Paediatr Scand 1989; 78:767.
  22. Siegel RL, Issekutz T, Schwaber J, et al. Deficiency of T helper cells in transient hypogammaglobulinemia of infancy. N Engl J Med 1981; 305:1307.
  23. FUDENBERG HH, FUDENBERG BR. ANTIBODY TO HEREDITARY HUMAN GAMMA-GLOBULIN (GM) FACTOR RESULTING FROM MATERNAL-FETAL INCOMPATIBILITY. Science 1964; 145:170.
  24. Soothill JF. Immunoglobulins in first-degree relatives of patients with hypogammaglobulinaemia. Transient hypogammaglobulinaemia: a possible manifestation of heterozygocity. Lancet 1968; 1:1001.
  25. Rieger CH, Nelson LA, Peri BA, et al. Transient hypogammaglobulinemia of infancy. J Pediatr 1977; 91:601.
  26. Lentz D, Gershwin ME. Is transient hypogammaglobulinemia of infancy a manifestation of zinc deficiency? Dev Comp Immunol 1984; 8:1.
  27. Rutkowska M, Trzyna E, Lenart M, et al. The elevated number of circulating regulatory T cells in patients with transient hypogammaglobulinemia of infancy is not associated with any abnormalities in the genes encoding the TGF-β receptors. Clin Immunol 2013; 149:83.
  28. Wilson CB, Lewis DB, Penix LA. The physiologic immunodeficiency of immaturity. In: Immunologic disorders in infants and children, Stiehm ER (Ed), WB Saunders, Philadelphia 1996. p.253.
  29. Artac H, Kara R, Gokturk B, Reisli I. Reduced CD19 expression and decreased memory B cell numbers in transient hypogammaglobulinemia of infancy. Clin Exp Med 2013; 13:257.
  30. Dorsey MJ, Orange JS. Impaired specific antibody response and increased B-cell population in transient hypogammaglobulinemia of infancy. Ann Allergy Asthma Immunol 2006; 97:590.
  31. van Zelm MC, Reisli I, van der Burg M, et al. An antibody-deficiency syndrome due to mutations in the CD19 gene. N Engl J Med 2006; 354:1901.
  32. Fineman SM, Rosen FS, Geha RS. Transient hypogammaglobulinemia, elevated immunoglobulin E levels, and food allergy. J Allergy Clin Immunol 1979; 64:216.
  33. Sumikawa Y, Kato J, Kan Y, et al. Severe atopic dermatitis associated with transient hypogammaglobulinemia of infancy. Int J Dermatol 2015; 54:e185.
  34. Moschese V, Carsetti R, Graziani S, et al. Memory B-cell subsets as a predictive marker of outcome in hypogammaglobulinemia during infancy. J Allergy Clin Immunol 2007; 120:474.
  35. Alachkar H, Taubenheim N, Haeney MR, et al. Memory switched B cell percentage and not serum immunoglobulin concentration is associated with clinical complications in children and adults with specific antibody deficiency and common variable immunodeficiency. Clin Immunol 2006; 120:310.
  36. Carsetti R, Rosado MM, Donnanno S, et al. The loss of IgM memory B cells correlates with clinical disease in common variable immunodeficiency. J Allergy Clin Immunol 2005; 115:412.
  37. Buckley RH. Immunodeficiency diseases. JAMA 1992; 268:2797.
  38. Iseki M, Heiner DC. Immunodeficiency disorders. Pediatr Rev 1993; 14:226.
  39. Vetrie D, Vorechovský I, Sideras P, et al. The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases. Nature 1993; 361:226.
  40. Kornfeld SJ, Kratz J, Haire RN, et al. X-linked agammaglobulinemia presenting as transient hypogammaglobulinemia of infancy. J Allergy Clin Immunol 1995; 95:915.
  41. Saffran DC, Parolini O, Fitch-Hilgenberg ME, et al. Brief report: a point mutation in the SH2 domain of Bruton's tyrosine kinase in atypical X-linked agammaglobulinemia. N Engl J Med 1994; 330:1488.
  42. Memmedova L, Azarsiz E, Edeer Karaca N, et al. Does intravenous immunoglobulin therapy prolong immunodeficiency in transient hypogammaglobulinemia of infancy? Pediatr Rep 2013; 5:e14.
  43. Rosen FS, Janeway CA. The gamma globulins. 3. The antibody deficiency syndromes. N Engl J Med 1966; 275:769.
  44. Doğu F, Ikincioğullari A, Babacan E. Transient hypogammaglobulinemia of infancy and early childhood: outcome of 30 cases. Turk J Pediatr 2004; 46:120.
  45. Centers for Disease Control and Prevention (CDC). Outbreak of hepatitis C associated with intravenous immunoglobulin administration--United States, October 1993-June 1994. MMWR Morb Mortal Wkly Rep 1994; 43:505.
  46. Rosen FS, Cooper MD, Wedgwood RJ. The primary immunodeficiencies (1). N Engl J Med 1984; 311:235.
Topic 5951 Version 15.0

All topics are updated as new information becomes available. Our peer review process typically takes one to six weeks depending on the issue.